New to peptides? Start with the foundations ->
The dad-test answer
Both target mitochondrial function and aging, but the evidence tier is different. NAD+ (and its precursors NMN and NR) has multiple human RCTs - small ones, but real ones - showing improved insulin sensitivity and elevated tissue NAD+. MOTS-c has one published human trial and a stack of cell and rodent papers. NAD+ is the more evidence-backed daily protocol; MOTS-c is the higher-upside biohacker bet that may not pan out.
Who wins for what
| Use case | Who wins, and why |
|---|---|
| human clinical evidence |
nad+ NMN raised muscle insulin sensitivity in prediabetic women (Yoshino et al., Science 2021); NR doubled blood NAD+ in healthy older adults (Martens et al., 2018). |
| muscle and exercise capacity in animal models |
mots-c Lee et al. 2015 (Cell Metabolism) showed MOTS-c reverses age-dependent decline in physical capacity in mice; the human Phase 1 in insulin resistance is consistent. |
| ease of access, oral form |
nad+ NMN and NR are sold as oral supplements with deep clinical trial records; MOTS-c is a research peptide requiring subQ injection. |
| novelty / mitochondrial signaling angle |
mots-c MOTS-c is encoded inside mitochondrial DNA itself; mechanism is genuinely different from NAD+ pathway support. |
What the head-to-head data shows
Neither molecule is FDA-approved for longevity in 2026. NAD+ has the broader human evidence base via its precursors. Yoshino et al., Science 2021 showed 250mg/day NMN for 10 weeks raised muscle insulin sensitivity in prediabetic postmenopausal women. Martens et al. 2018 showed nicotinamide riboside (1000mg/day) doubled blood NAD+ over 6 weeks in healthy middle-aged and older adults. MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA region, characterized by Lee et al., Cell Metabolism 2015 - the mouse work showed reversal of age-related insulin resistance and improved exercise capacity. A 7-day intravenous MOTS-c human trial reported improved insulin sensitivity in overweight insulin-resistant men, and a Phase 1 trial (NCT07505745) is studying MOTS-c for insulin sensitivity in adults. Direct injectable NAD+ is a separate protocol from oral NMN/NR and has thinner trial evidence than the oral precursors.
Our honest call
For a reader who wants the most defensible mitochondrial longevity protocol in 2026, oral NMN or NR is the move - the human trials exist, the safety record is solid, and the daily protocol is realistic to maintain. MOTS-c is interesting but the human evidence base is one Phase 1 trial and a handful of mechanistic papers. We are not against people running MOTS-c at 5-10mg subQ a few times a week, but we are honest that the evidence tier drops compared to the NAD+ precursors. The injectable NAD+ side of this comparison is the thinnest of all - lots of clinic marketing, very little controlled trial data. Read the protocol pages before running either.
Sources and citations
- Yoshino et al., NMN and muscle insulin sensitivity, Science 2021 (PMID 33888596)
- Martens et al., NR safety and NAD+ elevation, Nat Commun 2018 (PMID 29992272)
- Lee et al., MOTS-c reverses age-dependent metabolic decline, Cell Metabolism 2015 (PMID 25738459)
- Kim et al., MOTS-c regulates plasma metabolites, Physiol Rep 2019 (PMID 31293078)
- ClinicalTrials.gov NCT07505745 (MOTS-c for insulin sensitivity)
Where to go next
- Full MOTS-c directory entry
- MOTS-c dosing breakdown
- What are peptides - if you skipped the foundation
- All Protocol One comparisons
- How peptides actually work
- Subscribe to the dispatch
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine. None of this replaces a doctor. Peptides are gray-market in the US for most uses. Talk to a real prescriber before you change anything.